<p>Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial</p>-Reference-Cited by-同舟云学术

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial

Published:2020-12 Issue: Volume:Volume 13 Page:4993-5001
ISSN:1178-7007
Container-title:Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
language:en
Short-container-title:DMSO

Author:

Teragawa Hiroki^ORCID,Morimoto Takeshi^ORCID,Fujii Yuichi,Ueda Tomohiro,Sakuma Mio,Shimabukuro Michio,Arasaki Osamu,Node Koichi,Nomiyama Takashi,Ueda Shinichiro

Publisher

Informa UK Limited

Subject

Pharmacology,Internal Medicine

Reference35 articles.

1. Diabetes and Atherosclerosis

2. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

3. Japanese Legacy Cohort Studies: The Hisayama Study

4. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes

5. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a Stability-Indicating Related Substances RP-HPLC Method for Anagliptin and its Degradation Products;Pharmaceutical Chemistry Journal;2023-11

2. An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis;International Journal of Molecular Sciences;2023-04-24

3. Low-grade inflammation in type 2 diabetes: a cross-sectional study from a Danish diabetes outpatient clinic;BMJ Open;2022-12

4. Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment;Molecules;2022-05-10

5. Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2022-03